T
10.36
-0.27 (-2.54%)
| Previous Close | 10.63 |
| Open | 10.46 |
| Volume | 1,558,174 |
| Avg. Volume (3M) | 2,218,243 |
| Market Cap | 1,261,608,192 |
| Price / Book | 5.87 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -0.450 |
| Total Debt/Equity (MRQ) | 0.96% |
| Current Ratio (MRQ) | 15.38 |
| Operating Cash Flow (TTM) | -41.27 M |
| Levered Free Cash Flow (TTM) | -24.53 M |
| Return on Assets (TTM) | -34.41% |
| Return on Equity (TTM) | -55.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Trevi Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.6
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.63 |
|
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 79.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Octagon Capital Advisors Lp | 30 Jun 2025 | 3,672,000 |
| Affinity Asset Advisors, Llc | 30 Jun 2025 | 2,534,058 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 27.00 (Raymond James, 160.62%) | Buy |
| Median | 22.00 (112.36%) | |
| Low | 18.00 (Morgan Stanley, 73.75%) | Buy |
| Average | 22.33 (115.54%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 7.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 21 Aug 2025 | 18.00 (73.75%) | Buy | 7.49 |
| Needham | 08 Aug 2025 | 22.00 (112.36%) | Buy | 7.42 |
| Raymond James | 08 Aug 2025 | 27.00 (160.62%) | Buy | 7.42 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Oct 2025 | Announcement | Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting |
| 18 Sep 2025 | Announcement | Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025 |
| 28 Aug 2025 | Announcement | Trevi Therapeutics to Participate in Upcoming September Conferences |
| 07 Aug 2025 | Announcement | Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates |
| 31 Jul 2025 | Announcement | Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 |
| 29 Jul 2025 | Announcement | Trevi Therapeutics to Participate in Upcoming August Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |